team & partners

meet the team

Leen Limbourg

Leen Limbourg brings over 15 years of experience in the biopharmaceutical industry in international medico-marketing functions, development and strategic planning. Prior to becoming a founding partner of atoms & art, Leen was director medical & scientific affairs at TiGenix NV where she was the medical lead for the first authorized advanced therapy medicinal product and the strategic development of the stem cell platform. Between 2005 and 2009 she was member of the global launch team for the immunology franchise at UCB.
Leen started her career in the life science industry in 2000 at Organon, where she held various positions with increasing responsibilities in the medical and health economics department.
She holds a Medical Degree from the University of Leuven, studied strategic health economics at Stockholm School of Economics and received her MBA from Vlerick Leuven Ghent Management School. 


Robert Dekker

Robert Dekker is a founding partner of atoms & art. He has 18 years of international experience in biopharmaceutical research, regulatory affairs, product development and business development. From 2007 to 2014 Robert held several functions within TiGenix NV. He was director new product commercialization leading the cross-functional team on decision-making for new indications and strategic development of the technology platform.
Within business development, he was responsible for portfolio management through licensing and distribution agreements. As a member of the R&D department, he managed new product development and contributed to the marketing authorization of the first advanced therapy medicinal product.
Between 2002 and 2007 he was Scientific Assessor at the Medicines Evaluation Board in The Netherlands and a core member in the working party on cell-based products at the European Medicines Agency.
Robert holds a MSc degree in medical biology from the University of Amsterdam and a PhD in bone tissue engineering obtained at IsoTis BV.


meet our partners

EKOY investment partners